These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36298510)

  • 1. Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents.
    Puthanakit T; Chantasrisawad N; Yoohat K; Nantanee R; Sophonphan J; Meepuksom T; Sodsai P; Phanthanawiboon S; Jantarabenjakul W; Hirankarn N; Kosalaraksa P
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
    Chantasrisawad N; Puthanakit T; Kornsitthikul K; Jaru-Ampornpan P; Tawan M; Matapituk P; Sophonphan J; Anugulruengkitt S; Tangsathapornpong A; Katanyutanon A;
    Vaccine X; 2022 Dec; 12():100221. PubMed ID: 36213592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
    Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222.
    Nantanee R; Jantarabenjakul W; Jaru-Ampornpan P; Sodsai P; Himananto O; Athipunjapong J; Sophonphan J; Nanthapisal S; Hirankarn N; Puthanakit T;
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.
    Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Himananto O; Papakhee S; Sophonphan J; Tawan M; Jupimai T; Anugulruengkitt S; Puthanakit T;
    Vaccine X; 2023 Dec; 15():100367. PubMed ID: 37601322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
    Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
    Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Nantanee R; Aikphaibul P; Jaru-Ampornpan P; Sodsai P; Himananto O; Theerawit T; Sophonphan J; Tovichayathamrong P; Manothummetha K; Laohasereekul T; Hiransuthikul N; Hirankarn N; Puthanakit T;
    Vaccine; 2022 May; 40(24):3320-3329. PubMed ID: 35513961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases.
    Chantasrisawad N; Puthanakit T; Tangsathapornpong A; Techasaensiri C; Phongsamart W; Suwanpakdee D; Jaruampornpan P; Sophonphan J; Suntarattiwong P; Chotpitayasunondh T;
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine.
    Temtanakitpaisan Y; Saengnipanthkul S; Sarakosol N; Maskasame S; Mongkon S; Buranrat B; Thammawat S; Patamatamkul S; Nernsai P
    Vaccine X; 2022 Dec; 12():100242. PubMed ID: 36415450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
    Chantasrisawad N; Techasaensiri C; Kosalaraksa P; Phongsamart W; Tangsathapornpong A; Jaru-Ampornpan P; Sophonphan J; Suntarattiwong P; Puthanakit T;
    Int J Infect Dis; 2023 May; 130():52-59. PubMed ID: 36841501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
    Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
    Poparn H; Srichumpuang C; Sosothikul D; Jantarabenjakul W; Lauhasurayotin S; Techavichit P; Chiangthong K; Poovorawan Y
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2049-2055. PubMed ID: 35763647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose.
    Gareayaghi N; Demirci M; Ozbey D; Dasdemir F; Dinc HO; Balkan II; Saribas S; Saltoglu N; Kocazeybek B
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand.
    Jarupan M; Jantarabenjakul W; Jaruampornpan P; Subchartanan J; Phasomsap C; Sritammasiri T; Cartledge S; Suchartlikitwong P; Anugulruengkitt S; Kawichai S; Puthanakit T
    Vaccines (Basel); 2023 Apr; 11(5):. PubMed ID: 37242988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial.
    Pannus P; Depickère S; Kemlin D; Houben S; Neven KY; Heyndrickx L; Michiels J; Willems E; De Craeye S; Francotte A; Chaumont F; Olislagers V; Waegemans A; Verbrugghe M; Schmickler MN; Van Gucht S; Dierick K; Marchant A; Desombere I; Ariën KK; Goossens ME
    PLOS Glob Public Health; 2022; 2(12):e0001308. PubMed ID: 36962838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.